Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 3/20 | 0.69 |
| ▸ | FLT3 | P36888 | 3/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | JAK1 | P23458 | 2/20 | 0.69 |
| ▸ | WEE1 | P30291 | 2/20 | 0.69 |
| ▸ | JAK3 | P52333 | 2/20 | 0.69 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.69 |
| ▸ | BUB1B | O60566 | 1/20 | 0.69 |
| ▸ | BRD2 | P25440 | 1/20 | 0.69 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.69 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.56 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | STK25 | O00506 | 1/20 | 0.56 |
| ▸ | CIT | O14578 | 1/20 | 0.56 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | CASK | O14936 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30306499 | 1.00 | BRD4 (1.00) | BRD4JAK2FLT3RETJAK1 | |
| SCHEMBL17526042 | 0.92 | BRD4 (1.00) | BRD4JAK2FLT3RETJAK1 | |
| SCHEMBL30306454 | 0.92 | BRD4 (1.00) | BRD4JAK2FLT3RETJAK1 | |
| SCHEMBL17526325 | 0.90 | BRD4 (1.00) | BRD4JAK2FLT3RETJAK1 | |
| SCHEMBL30306393 | 0.90 | BRD4 (1.00) | BRD4JAK2FLT3RETJAK1 | |
| SCHEMBL263665 | 0.90 | BRD4 (0.84) | BRD4JAK2FLT3RETJAK1 | |
| SCHEMBL18757685 | 0.88 | BRD4 (1.00) | BRD4JAK2FLT3RETJAK1 | |
| SCHEMBL30306551 | 0.88 | BRD4 (1.00) | BRD4JAK2FLT3RETJAK1 | |
| SCHEMBL30306491 | 0.84 | BRD4 (1.00) | BRD4JAK2FLT3RETJAK1 | |
| SCHEMBL18757645 | 0.84 | BRD4 (1.00) | BRD4JAK2FLT3RETJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017066428-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2016022460-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | BRD4 1/4885JAK2 181/4885FLT3 980/4885 |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | BRD4 1/4885JAK2 181/4885FLT3 980/4885 |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | BRD4 1/4885JAK2 314/4885FLT3 724/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | BRD4 1/4885JAK2 181/4885FLT3 980/4885 |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | BRD4 1/4885JAK2 314/4885FLT3 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.